Physician profile
Taylor Bertone
NPI 1689326886
$1,663.41
in general payments reported to CMS, 2019-2025
14 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $203 · 2024: $814 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $330.32 | 2024-2025 | Opzelura, Opzelura |
| Abbvie INC. | $239.11 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $233.41 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $194.03 | 2023-2025 | Libtayo, Dupixent |
| Leo Pharma INC. | $106.39 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $104.23 | 2023-2025 | Odomzo, Blu-U |
| Janssen Biotech, INC. | $103.98 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $88.91 | 2023-2025 | |
| Amgen INC. | $70.08 | 2024-2025 | Otezla, Otezla |
| Convatec INC. | $57.94 | 2024-2025 | |
| Revance Therapeutics, INC. | $53.83 | 2025 | Daxxify |
| Lilly USA, LLC | $39.77 | 2023 | Olumiant |
| Ucb, INC. | $25.65 | 2025 | Bimzelx |
| Springworks Therapeutics, INC. | $15.76 | 2025 | Gomekli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Bertone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.